| A landscape of driver mutations in melanoma E Hodis, IR Watson, GV Kryukov, ST Arold, M Imielinski, JP Theurillat, ... Cell 150 (2), 251-263, 2012 | 2922 | 2012 |
| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | 1367 | 2016 |
| Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma JJ Gartner, SCJ Parker, TD Prickett, K Dutton-Regester, ML Stitzel, JC Lin, ... Proceedings of the National Academy of Sciences 110 (33), 13481-13486, 2013 | 198 | 2013 |
| Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma YNV Gopal, H Rizos, G Chen, W Deng, DT Frederick, ZA Cooper, ... Cancer research 74 (23), 7037-7047, 2014 | 191 | 2014 |
| Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target G Chen, N Chakravarti, K Aardalen, AJ Lazar, MT Tetzlaff, B Wubbenhorst, ... Clinical Cancer Research 20 (21), 5537-5546, 2014 | 187 | 2014 |
| Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations AD Bucheit, G Chen, A Siroy, M Tetzlaff, R Broaddus, D Milton, P Fox, ... Clinical Cancer Research 20 (21), 5527-5536, 2014 | 155 | 2014 |
| AKT1 Activation Promotes Development of Melanoma Metastases JH Cho, JP Robinson, RA Arave, WJ Burnett, DA Kircher, G Chen, ... Cell reports 13 (5), 898-905, 2015 | 145 | 2015 |
| Tumor-associated B-cells induce tumor heterogeneity and therapy resistance R Somasundaram, G Zhang, M Fukunaga-Kalabis, M Perego, C Krepler, ... Nature communications 8 (1), 1-16, 2017 | 128 | 2017 |
| Role and therapeutic potential of PI3K‐mTOR signaling in de novo resistance to BRAF inhibition W Deng, YN Vashisht Gopal, A Scott, G Chen, SE Woodman, MA Davies Pigment cell & melanoma research 25 (2), 248-258, 2012 | 128 | 2012 |
| Myeloid lineage of high proliferative potential human smooth muscle outgrowth cells circulating in blood and vasculogenic smooth muscle-like cells in vivo P Metharom, C Liu, S Wang, P Stalboerger, G Chen, B Doyle, Y Ikeda, ... Atherosclerosis 198 (1), 29-38, 2008 | 57 | 2008 |
| Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor–Refractory Metastatic Melanoma: A Phase 2 Clinical Trial G Chen, JL McQuade, DJ Panka, CW Hudgens, A Amin-Mansour, XJ Mu, ... JAMA oncology 2 (8), 1056-1064, 2016 | 53 | 2016 |
| Targeted therapy resistance mechanisms and therapeutic implications in melanoma G Chen, MA Davies Hematology/Oncology Clinics 28 (3), 523-536, 2014 | 40 | 2014 |
| RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma L Goedert, CG Pereira, J Roszik, JR Plaça, C Cardoso, G Chen, W Deng, ... Oncotarget 7 (24), 36711, 2016 | 32 | 2016 |
| Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin TD Prickett, B Zerlanko, JJ Gartner, SCJ Parker, K Dutton-Regester, ... Journal of Investigative Dermatology 134 (2), 452-460, 2014 | 32 | 2014 |
| Emerging insights into the molecular biology of brain metastases G Chen, MA Davies Biochemical pharmacology 83 (3), 305-314, 2012 | 30 | 2012 |
| Changes in retinal sensitivity associated with cotoretigene toliparvovec in X-linked retinitis pigmentosa with rpgr gene variations L von Krusenstiern, J Liu, E Liao, JA Gow, G Chen, T Ong, AJ Lotery, ... JAMA ophthalmology 141 (3), 275-283, 2023 | 10 | 2023 |
| Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular … JL McQuade, G Chen, DJ Panka, A Reuben, RL Bassett, A Joon, ... Journal of Clinical Oncology 33 (15_suppl), e20051-e20051, 2015 | 1 | 2015 |
| Molecular and clinical correlates of PTEN expression in melanoma MA Davies, G Chen, DD Liu, J Malke, JE Gershenwald, AJ Lazar Cancer Research 72 (8 Supplement), 968-968, 2012 | 1 | 2012 |
| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | | 2016 |
| RMEL3, a long noncoding RNA, induces tumor malignancy through the MAPK and PI3K pathways in BRAFV600E melanomas L Goedert, CG Pereira, J Roszik, JR Plaça, C Cardoso, G Chen, W Deng, ... Abstracts, 2016 | | 2016 |
